Rocket Lab Successfully Launches 10th Electron Mission for Multi-Launch Customer BlackSky
MAHIA, New Zealand--(BUSINESS WIRE)--Rocket Lab USA, Inc. (Nasdaq: RKLB) ('Rocket Lab' or 'the Company'), a global leader in launch services and space systems, today successfully launched its 65 th Electron to deploy Earth-imaging satellites for real-time space-based intelligence company BlackSky.
The 'Full Stream Ahead' mission lifted-off from Rocket Lab Launch Complex 1 in Mahia, New Zealand at 11:57 am NZST (23:57 UTC on June 2 nd), successfully deploying a Gen-3 satellite by BlackSky to a 470 km circular earth orbit and further expanding the company's low Earth orbit constellation. Gen-3 was also deployed from a Rocket Lab Motorized Lightband, a separation system for satellites that Rocket Lab has provided BlackSky for each of its launches on Electron to date.
'Full Stream Ahead' is the second in a series of four Electron launches booked by BlackSky to deploy its Gen-3 satellites to orbit this year, and the tenth overall launch for the company since 2019 – making Electron the go-to launch vehicle for BlackSky's constellation to date. Rocket Lab successfully deployed the first of BlackSky's new missions, 'Fasten Your Seatbelts', earlier this year in February 2025.
Launching just 16 days after Rocket Lab's prior Electron mission from Launch Complex 1, 'Full Stream Ahead' underscores Electron's reliability amid an accelerating launch cadence. This quick succession of launches with 100% mission success solidifies Electron as one of the world's most consistently and reliably utilized orbital launch vehicles.
Rocket Lab founder and CEO, Sir Peter Beck, said: 'Another successful mission to add to Electron's already stellar track record of providing reliable orbital access for constellation developers across the globe. We're laser-focused on delivering an increasing cadence of regular and reliable dedicated access to space for small satellite operators with Electron, and looking forward to continuing to deploy BlackSky's constellation with more Electron launches in the months to come.'
'With each successive launch BlackSky expands on-orbit capacity, introduces Gen-3 capabilities and furthers our ability to meet the demands of the most time-dominant missions. Our partnership with Rocket Lab has demonstrated exceptional agility in deploying capacity where and when our customers need it most,' said Brian O'Toole, BlackSky CEO.
Today's launch for BlackSky will be Electron's seventh successful mission of 2025, Rocket Lab's 65 th launch overall, and brings the total number of satellites delivered to space by Electron to 226.
Launch images: F65 | Full Stream Ahead | Flickr
Launch webcast: Rocket Lab - 'Full Stream Ahead' Launch - YouTube
+ About Rocket Lab
Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, satellite manufacture, spacecraft components, and on-orbit management solutions that make it faster, easier, and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle, a family of flight-proven spacecraft, and the Company is developing the large Neutron launch vehicle for constellation deployment. Since its first orbital launch in January 2018, Rocket Lab's Electron launch vehicle has become the second most frequently launched U.S. rocket annually and has delivered more than 200 satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab's Photon spacecraft platform has been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third launch pad in Virginia. To learn more, visit www.rocketlabcorp.com.
+ Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward looking statements contained in Section 27A of the Securities Act of 1933, as amended (the 'Securities Act') and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy are forward-looking statements. The words 'believe,' 'may,' 'will,' 'estimate,' 'potential,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'strategy,' 'future,' 'could,' 'would,' 'project,' 'plan,' 'target,' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the 'SEC'), accessible on the SEC's website at www.sec.gov and the Investor Relations section of our website at www.rocketlabusa.com, which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Meridianbet Seals Sponsorship Deal with Aquatic Sports Association of Malta (ASA)
Two-year agreement expands Meridianbet and Golden Matrix's (GMGI) sports sponsorship portfolio across regulated European markets Aquatic Sports Association of Malta VALLETTA, Malta, June 04, 2025 (GLOBE NEWSWIRE) -- Meridianbet, the sports betting and iGaming division of Golden Matrix Group Inc. (NASDAQ: GMGI), a leading developer and licensor of B2B and B2C gaming platforms, today announced the signing of a two-year exclusive sponsorship agreement with the Aquatic Sports Association of Malta (ASA), the official governing body for water polo, swimming, and artistic swimming in Malta. Under the terms of the agreement, Meridianbet becomes the exclusive betting partner of ASA, gaining integrated brand exposure across ASA events, digital platforms, and physical venues. The sponsorship includes the launch of the branded national cup competition - Meridianbet Super Cup, as well as LED road signage, scoreboard branding, and apparel sponsorships across Malta's aquatic sports federations. 'Water polo and aquatic sports are a vital part of Malta's sporting culture,' said Stefan Pavlovic, Malta territory director at Meridianbet. 'This partnership reflects our continued commitment to supporting national sports ecosystems, building long-term brand visibility in regulated markets, and delivering value to fans, players, local institutions and shareholders.' The ASA partnership builds on Meridianbet's growing sponsorship portfolio across 25+ international jurisdictions, where it supports sports ranging from football, basketball and MMA to eSports and grassroots competitions. This announcement also aligns with Meridianbet's broader ESG strategy. In 2024 alone, the company conducted 293 community engagement initiatives, reaching over 18,000 direct and indirect beneficiaries through education, healthcare, sports, and advocacy programs. Key Highlights of the Deal: Meridianbet named exclusive betting partner of Malta's ASA (governing body for water polo, swimming, artistic swimming) Launch of the Meridianbet Super Cup Brand exposure via LED ads, digital platforms, and team apparel To learn more about Meridianbet's community impact programs, visit About Meridianbet Founded in 2001, Meridianbet Group is a well-established online sports betting and gaming group, licensed and currently operating in 18 jurisdictions across Europe, Africa, and South America. The Meridianbet Group's successful business model utilizes proprietary technology and scalable systems, allowing it to operate in multiple countries and currencies with an omni-channel approach to markets, including retail, desktop online, and mobile. The Company is part of the Golden Matrix Group (Nasdaq: GMGI). For more information, visit IR Presentation - YouTube - Twitter - Email: ir@ A photo accompanying this announcement is available at
Yahoo
22 minutes ago
- Yahoo
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial
Sionna Therapeutics, Inc. (NASDAQ:SION) released data from its Phase 1 trials of SION-719 and SION-451, the company's first-in-class nucleotide-binding domain 1 (NBD1) stabilizers, in healthy volunteers. One hundred subjects were dosed in the SION-719 trial, and 110 subjects were dosed in the SION-451 trial. Data Highlights Both NBD1 stabilizers were generally well tolerated and achieved pharmacokinetic (PK) concentration targets established using Sionna's preclinical cystic fibrosis (CF) human bronchial epithelial (CFHBE) data reinforce the potential of both NBD1 stabilizers to provide clinically meaningful benefit for CF patients, including the potential for wild-type CFTR function, either as an add-on to standard of care (SOC), or in a proprietary dual combination with complementary modulators. Both compounds were generally well tolerated in the Phase 1 trials. There were no serious adverse events, treatment-emergent adverse events (TEAEs) that led to discontinuation of the drug, or dose-limiting TEAEs observed. Most TEAEs were mild to moderate. One Grade 1 TEAE related to liver function tests (LFTs) was observed in a SION-451-treated subject who tested positive for influenza; no TEAEs related to LFTs were observed in the other cohorts of SION-451. There were no TEAEs related to LFTs in SION-719-treated subjects. The data from Part C of each trial support the use of a tablet formulation in future studies and indicate that both compounds can be dosed in a fed or fasted state. SION-719 and SION-451 achieved the desired target PK concentrations at multiple doses twice daily. Both stabilizers met exposure thresholds that can provide clinically meaningful benefit if administered as an add-on to SOC or in a proprietary dual combination with complementary modulators. Next Steps For SION-719: Sionna is progressing SION-719 into a Phase 2a POC trial evaluating the compound as an add-on to SOC in CF patients. Sionna is on track to initiate this trial in the second half of 2025, with topline data anticipated in mid-2026. The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for SION-719. The first subject has been dosed in a midazolam drug-drug interaction (DDI) study to confirm that SION-719 can be dosed in combination with the SOC according to its label. The study will be completed before the Phase 2a trial is initiated. Next Steps For SION-451: Sionna plans to initiate a Phase 1 healthy volunteer dual combination trial evaluating SION-451 combined with SION-2222 (galicaftor) and SION-109. The trial will assess the safety, tolerability, and PK of varying doses of the dual combinations. It will inform the selection of a dual combination for a Phase 2b trial in CF patients. Sionna is on track to initiate the healthy volunteer trial in the second half of 2025, with topline data expected in mid-2026. In February, Sionna Therapeutics closed its upsized initial public offering of 12.18 million shares at $18.00 per share, with approximately $219.2 million in gross proceeds. Price Action: SION stock is trading higher by 6.80% to $15.47 at last check Wednesday. Read Next:Photo by Gorodenkoff via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
39 minutes ago
- Yahoo
Industrias Unidas, S.A. de C.V. Consolidated Results of Operations for Q1 2025
MEXICO CITY, June 04, 2025--(BUSINESS WIRE)--Industrias Unidas, S.A. de C.V. ("IUSA" or the "Company") has announced its unaudited results for the three months ended March 31 of 2025. Figures are unaudited and have been prepared in accordance with Mexican Financial Reporting Standards ("MFRS"), which are different in certain respects from Generally Accepted Accounting Principles in the United States ("U.S. GAAP"). The results from any interim period are not necessarily indicative of the results that may be expected for a full fiscal year. Unless stated otherwise, reference herein to "Pesos", "pesos", or "Ps." are to pesos, the legal currency of Mexico and references to "U.S. dollars", "dollars", "U.S. $" or "$" are to United States dollars, the legal currency of the United States of America. Except as otherwise indicated, all peso amounts are presented herein in pesos with purchasing power as of March 31, 2025, and in pesos with their historical value for other dates cited. The dollar translations provided in this document are calculated solely for the convenience of the reader using an exchange rate of Ps. 20.46 per U.S. dollar, the exchange rate published by Banco de Mexico, the country's central bank, on March 31, 2025. Three months ended March 31, 2025, compared to three months ended March 31, 2024. The following table summarizes our results of operations for the three months ending March 31, 2025, and 2024: (Figures in Millions of Pesos) For the year ended March31, 2024 2025 Revenues 6,236.3 8,876.0 Cost of Sales 4,803.3 6,922.3 Gross Profit 1,433.0 1,953.7 Selling and Administrative Expenses 630.8 805.4 Operating Income (Loss) 802.2 1,148.3 Other Expenses - Net 51.2 21.8 Comprehensive Financing Result 63.8 34.9 Taxes and Statutory Employee Profit Sharing 180.9 290.4 Equity in Income (Loss) of Associated Companies (16.0) (2.8) Consolidated Net Income (Loss) 720.3 911.8 D&A 71.5 82.2 EBITDA 1/ 873.7 1,230.5 1/ EBITDA for any period is defined as consolidated net income (loss) excluding i) depreciation and amortization, ii) total net comprehensive financing result (which is comprised of net interest expense, exchange gain or loss, monetary position gain or loss and other Financing costs), iii) other expenses net, iv) income tax and statutory employee profit sharing and v) equity in income (loss) of associated companies. EBITDA should not be considered as an alternate measure of net income or operating income, as determined on a consolidated basis using amounts derived from statements of operations prepared in accordance with MFRS, or as an indicator of operating performance or to cash flows from operating activity as a measure of liquidity. EBITDA is not a recognized term under MFRS or U.S. GAAP and does not purport to be an alternative to net income as a measure of operating performance or to cash flows from operating activity as a measure of liquidity. Our consolidated net income for the three months ended March 31, 2025, was Ps.911.8 million (U.S.$44.6 million), compared to a net income of Ps.720.3 million in the same period of 2024. This represented a 26.6% increase, quarter over quarter (Q/Q). This change is primarily due to an increase in sales and hence Gross Profit. Revenues Our net revenues for the three months of 2025 increased 42.3% to Ps.8,876.0 million (U.S.$433.82 million) from Ps.6,236.3 million in the same period of 2024. This increase was driven in part by higher copper prices, combined with an increase in volume of sales. Our costs and revenues follow copper prices very closely since the market practice is to pass on to the buyer changes in raw material prices. Our sales are primarily for customers engaged in commercial, industrial and residential construction, and their related maintenance and renovation activities. We also sell to customers engaged in electrical power generation, transmission and distribution and to the sectors of gas, water and air conduction in Heating, Ventilation, Air conditioning and Refrigeration (HVACR). Our revenues consist mainly of sales of copper-based products (tubing, wire, cable and alloys) and electrical products. By country of production, approximately 61.3% of our revenues in the three months ended March 31, 2025, came from products manufactured in Mexico and the remaining 38.7% from products manufactured in the U.S. In terms of sales by region during the three months ended March 31, 2025, we derived approximately 44.0% of our revenues from sales to customers in the United States, 51.7% from customers in Mexico and 4.3% from the rest of the world ("ROW"). Cost of sales Our cost of sales in the three months ended March 31, 2025, increased by 44.1% to Ps.6,922.3 million (U.S.$338.3 million) from Ps.4,803.3 million in the same period of 2024. As a percentage of revenues, the cost of sales was 78.0% and 77.0% respectively. We reduce our cost base through several initiatives, including plant scheduling, raw material handling, and overall manufacturing overhead costs. According to our accounting policies, we make an inventory valuation at an average purchase price. In the case of copper cathodes, an aftermath adjustment is required due to the quotation period agreed with the suppliers (M+1). This initiative allows us to hedge purchases for 30 days at no additional cost. The adjustment is recorded to the cost of sales in the month in which it occurs. Gross Profit Our gross profit in the three months ended March 31, 2025, increased 36.3% to Ps.1,953.7 million (U.S.$95.5 million) from Ps.1,433.0 million in the same period of 2024. As a percentage of sales, gross profit in 2025 was 22.0% vs 23.0% in 2024. Selling and Administrative Expenses Our sales and administrative expenses in the three months ended March 31, 2025, increased 27.7% to Ps.805.4 million from Ps.630.8 in the same period of 2024. Operating Income Our operating income in the three months ended March 31, 2025, increased 43.1% to Ps. 1,148.3 million (U.S.$56.12 million) from an operating income of Ps. 802.2 in the same period of 2024. EBITDA In the three months ended March 31, 2025, our EBITDA increased 40.8% to Ps.1,230.5 million (or U.S.$60.1million), from Ps.873.7 million in the same period of 2024. The corresponding depreciation and amortization figures are Ps.422.3 million for January to March 2025 and Ps.337.7 million for the same period of 2024. Comprehensive Financing Result The following table shows our comprehensive financing results for the three months ending March 31, 2025, and 2024: (Figures in Millions of Pesos) For the year ended March 31, 2024 2025 Interest Expense (69.4) (78.5) Interest Income 51.3 30.6 Exchange Gain (Loss) - Net 88.7 88.9 Other Financing Costs (6.8) (6.1) Comprehensive Financing Result 63.8 34.9 Our comprehensive financing result in the three months ending March 31, 2025, was an expense of Ps.34.9 million, compared to an expense of Ps.63.8 million in the same period of 2024. Taxes and Statutory Employee Profit Sharing The provision for current and deferred income taxes and statutory employee profit sharing in the three months ended March 31, 2025, was an expense of Ps.290.4 million compared to an expense of Ps.180.9 million in the same period of 2024. Consolidated Net Income Our consolidated net income for the three months ended March 31, 2025, was Ps.911.8 million (U.S.$44.5 million), compared to a net income of Ps.720.3 million in the same period of 2024. Liquidity and Capital Resources Liquidity As of March 31, 2025, we had cash and cash equivalents for Ps.6,436.8 million (U.S.$314.6 million). Our policy is to invest available cash in short-term instruments issued by Mexican and U.S. banks as well as in securities issued by the governments of Mexico and the U.S. Our cash flow from operations and operating margins are significantly influenced by world market prices for raw copper, as quoted by COMEX and the London Metal Exchange ("LME"). Copper prices are subject to significant market fluctuations; average copper prices increased 18.4% in the three months ending March 31, 2025, to $4.57 US dollars per pound from $3.86 US dollar per pound in the same period of 2024. We obtain short-term financing from various sources, including Mexican and international banks. Short-term financing consists in part of lines of credit denominated in pesos and dollars. As of March 31, 2025, our outstanding short-term debt, including the current portion of long-term debt totaled Ps.422.2 million (U.S.$20.6 million), all of which was dollar denominated. On the same date, our outstanding consolidated long-term debt, excluding current portion thereof, totaled Ps.4,129.0 million (U.S.$201.8 million), all of which was dollar denominated. Accounts receivable from third parties as of March 31, 2025, were Ps.6,205.1 million (U.S.$303.3 million). Days outstanding in the domestic market were 31 days as of March 31, 2025. Debt Obligations The following table summarizes our debt as of March 31, 2025: Consolidated debt March 31, 2025 (In Millions of Pesos) U.S. subsidiaries debt 35.9 Mexican debt 4,515.4 Total 4,551.3 This total includes the restructured debt of the Company. Capital Expenditures For the three months ended March 31, 2025, we invested Ps.79.1 million (U.S. $3.9 million) in capital expenditure projects, mainly related to expansion of production and maintenance. In the three months ending March 31, 2025, our capital expenditures were allocated by segments as follows: 1.0% to copper tubing, 35.0% to wire and cable, 45.0% to valves and controls, 8.0% to electrical products and the remaining and 11.0% to other divisions. By geographic region 69.0% of total capital expenditures were invested in our Mexican facilities and the remaining 31.0% in the U.S. You should read this document in conjunction with the unaudited consolidated financial statements as of March 31, 2025, including the notes to those statements. View source version on Contacts Francisco Rodriguez, frodriguez@ tel. 5255 5216 4028
